Panbela Therapeutics (NASDAQ: PBLA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.250 | -0.270 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Panbela Therapeutics (NASDAQ: PBLA) through any online brokerage.
Other companies in Panbela Therapeutics’s space includes: Cellectar Biosciences (NASDAQ:CLRB), Addex Therapeutics (NASDAQ:ADXN), Brickell Biotech (NASDAQ:BBI), Calithera Biosciences (NASDAQ:CALA) and Biophytis (NASDAQ:BPTS).
The latest price target for Panbela Therapeutics (NASDAQ: PBLA) was reported by Roth Capital on Monday, June 28, 2021. The analyst firm set a price target for 10.00 expecting PBLA to rise to within 12 months (a possible 589.66% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Panbela Therapeutics (NASDAQ: PBLA) is $1.45 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Panbela Therapeutics.
Panbela Therapeutics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Panbela Therapeutics.
Panbela Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.